

Special Issue

B Lymphocytes (B Cells) and Derived Antibodies

Message from the Guest Editors

B lymphocytes, commonly termed "B cells", generate antibodies that are a key feature of the body's defense against infectious diseases and other illnesses, but in autoimmune dyscrasias can produce antibodies against self-components (autoantibodies) that participate in tissue destruction. Thus, proper activation and modulation of B cell activity is critical to the generation of correctly targeted and appropriately sized responses. This special Issue will strive to present all facets of B cells with a focus on B cells development, B cells activation and antibody production, B cells respond to external signals, B cells functions influenced by age and disease, antibody repertoire, and vaccine development. The goal of this issue is to provide readers a comprehensive insight into the increasingly important role of B cells and antibody in both clinical and research laboratories. We are inviting original research articles, reviews, mini-reviews, and methods discussing the multifaceted roles of B cells and antibodies.

Guest Editors

Dr. Naeem Khan

Center for Immunobiology, WMU Homer Stryker MD School of Medicine, Kalamazoo, MI 49007-7000, USA

Dr. Ajay Suresh Akhade

Institute for Systems Biology, University of Washington, Seattle, WA 98109, USA

Deadline for manuscript submissions

closed (30 April 2022)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/80194

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).